# China Launches 2026 National Patent Priority Examination Program to Accelerate High-Value IP Commercialization # China's National Intellectual Property Administration Unveils 2026-Oriented Patent Examination Quality &
siRNA drugs have become one of the fastest-growing innovative therapies in the biopharmaceutical field in recent years. The biggest difference between them and traditional drugs is:
Opening Introduction: In the first half of 2026, the total overseas licensing transaction volume of China’s innovative drugs will exceed $110 billion, accounting for 80% of
# China's Recent IP Law Enforcement and Judicial Updates: Key Progress in Cross-Border Protection, Digital IP and Right Remedy # UK IPO Updates 2024 Examination Guidelines
Editor’s Note: From Innovation to a Partner-Ready Asset Welcome to Global Innovation Asset Watch, a MeritsIP publication examining how emerging life science programs can translate into
Editor’s Note: From Innovation to a Partner-Ready Asset Welcome to Global Innovation Asset Watch, a MeritsIP publication examining how emerging life science programs can translate into
Editor’s Note: From Innovation to a Partner-Ready Asset Welcome to Global Innovation Asset Watch, a MeritsIP publication examining how emerging life science programs can translate into
Editor’s Note: From Innovation to a Partner-Ready Asset Welcome to Global Innovation Asset Watch, a MeritsIP publication examining how emerging life science programs can translate into
· Jiangsu: 81 Projects Win China Patent Awards · Beijing: 104 Invention Patents Win 26th China Patent Award · Second Session of the 26th China Patent
Editor’s Note: From Innovation to a Partner-Ready Asset Welcome to Global Innovation Asset Insight, a MeritsIP publication examining how emerging life science programs can translate into